

IPI-3063

Catalog No: tcsc0042285



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

1425043-73-7

Formula:

$C_{25}H_{25}N_7O_2$

Pathway:

PI3K/Akt/mTOR

Target:

PI3K

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 83.33 mg/mL (182.94 mM)

Observed Molecular Weight:


455.51

Product Description

IPI-3063 is a potent and selective **PI3K p110 δ** inhibitor with an **IC₅₀** of 2.5 ± 1.2 nM.

IC₅₀ & Target: IC₅₀: 2.5±1.2 nM (p110δ), 1171±533 nM (p110α), 1508±624 nM (p110β), 2187±1529 nM (p110γ)^[1]

In Vitro: IPI-3063 inhibits p110α, p110β, and p110γ with IC₅₀s of 1171±533 nM, 1508±624 nM, and 2187±1529 nM, respectively. IPI-3063 potently reduces mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1. IPI-3063 is a p110δ selective compound with an IC₅₀=0.1 nM in p110δ-specific cell-based assays and cellular IC₅₀ values for the other class I PI3K isoforms are at least 1,000-fold higher (IC₅₀=1901±1318 nM for p110α, IC₅₀=102.8±35.7 nM for p110β, IC₅₀=418.8±117.2 nM for p110γ). IPI-3063 is very potent in reducing p-AKT (significant effect at 1 nM). IPI-3063 also reduces p-ERK1/2 with a significant effect at 10 nM. IPI-3063 is very potent, achieving a significant decrease in B cell survival when present at 10 nM^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!